Applied Sciences (Nov 2021)

Targeted Protein Profiling of In Vivo NIPP-Treated Tissues Using DigiWest Technology

  • Felix Ruoff,
  • Melanie Henes,
  • Markus Templin,
  • Markus Enderle,
  • Hans Bösmüller,
  • Diethelm Wallwiener,
  • Sara Y. Brucker,
  • Katja Schenke-Layland,
  • Martin Weiss

DOI
https://doi.org/10.3390/app112311238
Journal volume & issue
Vol. 11, no. 23
p. 11238

Abstract

Read online

Non-invasive physical plasma (NIPP) is a novel therapeutic tool, currently being evaluated for the treatment of cancer and precancerous lesions in gynecology and other disciplines. Additionally, patients with cervical intraepithelial neoplasia (CIN) may benefit from NIPP treatment due to its non-invasive, side-effect-free, and tissue-sparing character. However, the molecular impact of in vivo NIPP treatment needs to be further investigated. For this purpose, usually only very small tissue biopsies are available after NIPP treatment. Here, we adapted DigiWest technology, a high-throughput bead-based Western blot, for the analysis of formalin-fixed paraffin-embedded (FFPE) cervical punch biopsies with a minimal sample amount. We investigated the molecular effects of NIPP treatment directly after (0 h) and 24 h after in vivo application. Results were compared to in vitro NIPP-treated human malignant cervical cells. NIPP effects were primarily based on an inhibitory impact on the cell cycle and cell growth factors. DigiWest technology was suitable for detailed protein profiling of small, primary FFPE biopsies.

Keywords